Skip to content

18F-FECh-PET in patients with brain tumors

18F-FECh-PET in patients with brain tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-003227-35-IT
Enrollment
60
Registered
2012-03-06
Start date
2011-10-04
Completion date
Unknown
Last updated
2014-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumors MedDRA version: 14.1 Level: LLT Classification code 10061030 Term: Brain tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Pharmaceutical Form: Solution for injection INN or Proposed INN: CHOLINE CAS Number: 62497 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 370-

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with brain tumours at first diagnosis or with suspicion of recurrence after treatment age 18-75 years Patients who provide the written informed consent Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: pregnancy/feeding

Design outcomes

Primary

MeasureTime frame
Main Objective: to dinstinguish the tumors border from normal brain and to identify the tumour's infiltration for choosing the most appropriate treatment to differentiate between the recurrence from fibrosis/necrosis;Secondary Objective: nd;Primary end point(s): to dinstinguish the tumors border from normal brain and to identify the tumour's infiltration for choosing the most appropriate treatment to differentiate between the recurrence from fibrosis/necrosis;Timepoint(s) of evaluation of this end point: 1 day

Secondary

MeasureTime frame
Secondary end point(s): nd;Timepoint(s) of evaluation of this end point: nd

Countries

Italy

Contacts

Public ContactMedicina Nucleare-Centro PET-TC

Policlinico Gemelli

ml.calcagni@rm.unicatt.it0630154978

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026